ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Core Viewpoint - ANI Pharmaceuticals, Inc. has launched Pentoxifylline Extended-Release (ER) Tablets, a generic version of Trental®, targeting a U.S. market valued at approximately $19.7 million annually [1][2]. Company Overview - ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription products, particularly for diseases with high unmet medical needs [3]. - The company aims to achieve sustainable growth by expanding its Rare Disease business and enhancing its generics business through improved research and development capabilities [3]. Product Launch - The launch of Pentoxifylline ER Tablets is part of ANI's strategy to continue momentum in its generics business within a limited competition market [2]. - The company emphasizes a patient-first approach, ensuring access to high-quality therapeutics for patients and healthcare providers [2].